New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF
AMSTERDAM, The Netherlands, June 30 /PRNewswire/ --
- "Study Could Have Major Impact on the Decision-Making Process With
Respect to Infertility Treatment"
New data from an economic analysis presented today at this year's
European Society of Human Reproduction and Embryology (ESHR...
Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
- Late-Breaking Data from Pivotal BLOOM Trial Presented at the American Diabetes Association's 69th Scientific Sessions Expand on Previously Announced Positive Top-Line Results -
NEW ORLEANS, June 6, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today...
Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
First-Ever Trial to Evaluate Whether Olmesartan Medoxomil Prevents Onset of Early Kidney Disease in Type 2 Diabetes Patients
SAN FRANCISCO, May 8 /PRNewswire/ -- Blinded one-year blood pressure (BP) reduction data from the ongoing landmark study ROADMAP ( R andomized O lmesartan A nd D ...
China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
HARBIN, China, May 4 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI ), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the R...
Comparative Study Shows Significant Bone In-growth and Advanced Clinical Outcomes Using Zimmer's Trabecular Metal(TM) Technology
10-Year Study Highlights Trabecular Metal Technology's Clinical Success Over Traditional Metal Implants
WARSAW, Ind., Feb. 25 /PRNewswire-FirstCall/ -- Zimmer Holdings, Inc. (NYSE: ZMH ; SWX: ZMH), a leader in the orthopaedic industry, today announced that data from an independent 10-ye...
Bone Biologics Announces Significant Milestone for Spinal Fusion Surgery Using Recombinant Protein and Demineralized Bone Matrix
Primate trials validate efficacy of the process
THOUSAND OAKS, Calif., Feb. 24 /PRNewswire/ -- Bone Biologics, Inc. announced today that it has successfully completed the initial primate trials validating the efficacy of the proprietary bone growth regeneration UCB-1 (NELL-1) protein in spina...
Oridion Announces Significant Medical Studies Presented at STA
JERUSALEM and NEEDHAM, Massachusetts, February 2 /PRNewswire-FirstCall/
-- Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN). During the recent annual
meeting of the Society for Technology in Anesthesia (STA) San Antonio, Texas,
major new findings from numerous medical research projects demonst...
Biotica Strikes Significant Collaboration Deal With GlaxoSmithKline
CAMBRIDGE, England, January 12 /PRNewswire/ -- Biotica Technology
Limited, a privately-held biotechnology company, announces a significant
Collaboration and License Agreement with GlaxoSmithKline to discover, develop
and commercialise novel erythromycin-based macrolides in inflammatory
New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia
US Oncology Affiliated Physicians Participate in ASH Conference
SAN FRANCISCO, Dec. 8 /PRNewswire/ -- A leading cancer researcher affiliated with the US Oncology Research Network will present findings from a randomized, multicenter Phase III trial that compared FCR and PCR in patients wit...
PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients
- PTC124 Highlighted in Multiple Presentations at North American Cystic
Fibrosis Conference -
SOUTH PLAINFIELD, N.J. and ORLANDO, Fla., Oct. 24 /PRNewswire/ -- PTC
Therapeutics, Inc. (PTC) today announced that results from a randomized
Phase 2a European study demonstrated that treatment with...
Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period
Results of FLEXX Trial Presented at the Osteoarthritis Research Society
International's 2008 World Congress
PARSIPPANY, N.J., Oct. 7 /PRNewswire/ -- Ferring Pharmaceuticals Inc.
recently presented results from the FLEXX Trial of Osteoarthritis of the
Knee, showing that EUFLEXXA(R) (1% sodium...
Concord Grape Juice Has No Significant Impact on Body Weight
Recent study revealed that drinking polyphenol-rich 100% Concord grape
juice was not associated with changes in appetite, energy intake or body
CONCORD, Mass., Oct. 6 /PRNewswire/ -- Regular consumption of 100%
polyphenol-rich Concord grape juice did not cause significant
Radioactive Seed Therapy Shows Significant Reduction in Lung Cancer Recurrence
Study Shows near 80% Improvement In Outcomes
PITTSBURGH, Sept. 23 /PRNewswire/ -- Radiation oncologists at Allegheny
General Hospital (AGH) in Pittsburgh today will report to the American
Society for Therapeutic Radiology and Oncology (ASTRO) in Boston that a
newer, minimally inv...
Bionovo's MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
EMERYVILLE, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Bionovo, Inc.
(Nasdaq: BNVI ) today announced that its lead drug candidate, MF101, for
menopausal hot flashes, showed improved sleep quality for women in a Phase
2 study completed earlier this year. The Company previously announced that
Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
Clinical Data Presented at American Academy of Dermatology Summer Meeting
PRINCETON, N.J., July 31 /PRNewswire/ -- NeoStrata today announced
findings from an ongoing 12-week study that demonstrates benefits of a
novel topically applied LCD (coal tar) solution (Psorent(TM)) versus
The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer
- Nexavar is First Approved Systemic Therapy to Treat the Disease -
WAYNE, N.J. and EMERYVILLE, Calif., July 23 /PRNewswire-FirstCall/ --
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq:
ONXX) today announced that The New England Journal of Medicine published
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
EORTC 18991 Phase III Study Results Published in The Lancet
KENILWORTH, N.J., July 11 /PRNewswire-FirstCall/ -- Today,
Schering-Plough (NYSE: SGP ) and the EORTC announced that long-term
treatment with pegylated interferon alfa-2b in stage III melanoma patients
had a significant
Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers' Diarrhea Vaccine
GAITHERSBURG, Md. and VIENNA, Austria, June 11 /PRNewswire-FirstCall/
-- Iomai Corporation (Nasdaq: IOMI ) today announced the publication of data
from the company's positive Phase II field study of its travelers' diarrhea
vaccine in The Lancet. The study, which analyzed data from 170 travele...
Phase 3 Results for Alogliptin Demonstrated Significant Blood Sugar Reductions in Monotherapy and Four Add-on Therapy Studies
Data from five pivotal phase 3 studies presented at the American Diabetes Association 68th Scientific Sessions
SAN FRANCISCO, June 7 /PRNewswire/ -- Results from five pivotal phase 3
studies of alogliptin were announced today at the American Diabetes
Association (ADA) 68th Scie...
Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
- Zometa when added to hormone therapy, following surgery, significantly reduced the risk of cancer returning or death by 36% beyond clinical benefits achieved with hormone therapy alone(1) - Findings may allow clinicians to improve standard of care for
premenopausal women diagn...
New Study Linking 'High Normal' Blood Pressure to Significant Cardiovascular Risk
- AtCor Medical's SphygmoCor system plays key role in discovery
ITASCA, Ill. and SYDNEY, Australia, May 28 /PRNewswire-FirstCall/ -- A
new study of more than 10,000 patients, conducted by the Universities of
Cambridge and Cardiff in the United Kingdom using AtCor Medical Holdings
TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
SAN MARINO, Calif., May 22 /PRNewswire/ -- Epeius Biotechnologies
announced today the promising results of an on-going United States-based
Phase I/II study of Rexin-G for metastatic breast cancer that is refractory
to conventional chemotherapy (J Clin Oncol 26:14509, 2008). This clinical
Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
First Presentation of Full Data Set from the TRIUMPH-1 Trial of Inhaled Treprostinil
SILVER SPRING, Md., May 21 /PRNewswire-FirstCall/ -- United
Therapeutics Corporation (Nasdaq: UTHR ) and its wholly-owned subsidiary
Lung Rx, Inc. today announced that data from s...
Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
- Study shows significantly improved bronchodilation and symptom control with combination therapy -
NAPA, Calif., May 20 /PRNewswire/ -- A newly published study presents
data demonstrating that patients with Chronic Obstructive Pulmonary Disease
(COPD), including emphysem...
Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
-- Clinical trial data for Perforomist(TM) (Formoterol Fumarate) Inhalation Solution presented at International ATS Conference --
NAPA, Calif., May 20 /PRNewswire/ -- Data presented today at the
International Conference of the American Thoracic Society (ATS) demonstrate
that concomitant ...
Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
CHICAGO, May 20 /PRNewswire/ -- GlaxoSmithKline and Synta
Pharmaceuticals Corp. (Nasdaq: SNTA ) today announced positive Phase II
clinical data for elesclomol (formerly STA-4783), an investigational agent
currently in development for metastatic melanoma. A retrospective analysis
showed that s...
Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
Single Molecule with Dual Mechanism May Offer Novel Approach to Blood Pressure Management
NEW ORLEANS, May 16 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq:
PCOP), an innovator in the discovery and development of novel small
molecule therapeutics, announced today tha...
Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions
Patch Formulation May Provide New Option for Clinicians Concerned About Systemic Exposure When Using an Oral NSAID
TAMPA, Fla., May 8 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE: ALO ),
a leading global specialty pharmaceutical company, announced today that two
studies to be p...
Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
WASHINGTON, May 7 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP,
Nasdaq: SHPGY), the global specialty biopharmaceutical company, presented
today at a major scientific meeting findings from analyses of pivotal trial
results of INTUNIV, a selective alpha-2A-agonist. This compound is an
Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
NEWPORT NEWS, Va., April 29 /PRNewswire/ -- Recently published data in
The American Journal of Surgery by a group of surgeons from Legacy Good
Samaritan Hospital in Portland, Oregon, demonstrates the value of using
Breast-Specific Gamma Imaging (BSGI) for the clinical management of breast
BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
- BiPar Sciences Presents First Peer-Reviewed Preclinical Results for BSI-201 at 2008 AACR Annual Meeting -
SAN DIEGO, April 14 /PRNewswire/ -- BiPar Sciences, Inc. today
announced positive preclinical data demonstrating the activity of its lead
poly ADP-ribose polymerase (PAR...
Bertrand Study Finds Significant Value in Breast-Specific Gamma Imaging (BSGI) as an Adjunctive Procedure in Breast Diagnostics
Presented at Miami Breast Cancer Conference, study demonstrates BSGI is both patient and cost effective.
NEWPORT NEWS, Va., March 6 /PRNewswire/ -- A recent study performed by
Dr. Margaret Bertrand, Director of Breast Imaging at Solis Bertrand Breast
Center in Greensboro, No...
On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
ANN ARBOR, Mich., Feb. 19 /PRNewswire/ -- Compendia Bioscience, Inc.
today announced results of a second productive year, including a renewed
and expanding commitment from all major customers and the addition of
several "Top 20" oncology drug companies to its customer roster. The new
Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
BEIJING, Feb. 6 /Xinhua-PRNewswire-FirstCall/ -- Lotus Pharmaceuticals,
Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a
pharmaceutical company in the People's Republic of China ("PRC"), today
announced that it has achieved significant
milestones in the development of
Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
Achieves Statistically Significant
ACR20, ACR50 & ACR70 Results
SOUTH SAN FRANCICSO, Calif., Dec. 13 /PRNewswire-FirstCall/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that its oral syk
kinase inhibitor, R788 (tamatinib fosdium), has demonstrated statistically
PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
Data Presented at the American Society of Hematology (ASH) Annual Meeting Publication Number: 840
CHESHIRE, Conn., Dec. 11 /PRNewswire-FirstCall/ -- Soliris(R)
(eculizumab) therapy reduced hemolysis, fatigue, thromboses (blood clots)
and transfusion requirements in patien...
Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
Published Results Also Show Potentially Differentiating Pharmacokinetic Profile of Prodrug Stimulant
PHILADELPHIA, Nov. 29 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP,
Nasdaq: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company,
today announced that Biologic...
Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
NEW YORK, Nov. 8 /PRNewswire/ -- Total daily dosages of milnacipran 100
mg and 200 mg demonstrated statistically significant
meaningful improvements in both pain and other core symptoms associated
with fibromyalgia syndrome (FMS), according to Phase III data presented
this week ...
Two Pivotal Phase III Studies for Roche's ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
- New data from TOWARD study highlight significant
improvements in RA symptoms achieved with the unique inhibiting action of ACTEMRA that specifically targets interleukin-6 receptors -
NUTLEY, N.J., Nov. 7 /PRNewswire-FirstCall/ -- Data from two pivotal
multinational Phase III cl...
Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease
LEXINGTON, Mass., Nov. 7 /PRNewswire/ -- ActivBiotics, Inc. today
announced the results of its PROVIDENCE-1 clinical trial, which evaluated
the effect of rifalazil in the treatment of intermittent claudication,
associated with peripheral arterial disease (PAD). The results demonstrated